www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/663

Title: Using the 'expected' survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer
Authors: BUYSE, Marc
BURZYKOWSKI, Tomasz
Parmar, Mahesh
Torri, Valter
Omura, George
Colombo, Nicoletta
Williams, Chris
Conte, Pierfranco
Vermorken, Jan
Keywords: Statistical methodology
Clinical trials
Issue Date: 2003
Publisher: AMER SOC CLINICAL ONCOLOGY
Citation: Journal of Clinical Oncology, 21(9). p. 1682-1687
Abstract: Purpose: A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP, P = .009). in contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P = .98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves. Materials and Methods: A proportional hazards model, fitted to the meta-analysis data, was used to construct the expected survival curve for each treatment arm of the ICON2 trial. Expected survival curves were compared with observed survival curves in the ICON2 trial at all time points using a nonparametric test. Results: The prognostic model for survival obtained in the meta-analysis included extent of residual disease, age, histologic grade, and International Federation of Gynecology and Obstetrics stage. When this model was applied to the ICON2 data, there was no difference between the expected and observed curves in the CAP arm. In contrast, the observed survival curve for carboplatin was far superior to the expected survival curve for CP (P < .01). Conclusion: These analyses provide indirect evidence that better results are achieved with carboplatin alone at an optimally tolerated dose, compared with the CP combination at a cisplatin dose of 50 to 60 mg/m(2). The expected survival may provide valuable insight when direct comparisons between randomized groups yield discrepant results across different studies.
URI: http://hdl.handle.net/1942/663
DOI: 10.1200/JCO.2003.04.088
ISI #: 000182585100006
ISSN: 0732-183X
Category: A1
Type: Journal Contribution
Validation: ecoom, 2004
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A96.61 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.